NAV
$53.04
AUM
$44.6M
Expense Ratio
-
Dividend Yield
0.00%
Beta
1.23
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +37.09% | +30.00% | +23.56% | +164.43% | +31.41% | +1.55% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | ERAS | Erasca Inc | 2.64% |
| 2 | TNGX | Tango Therapeutics Inc | 1.74% |
| 3 | ELVN | Enliven Therapeutics Inc | 1.73% |
| 4 | DNTH | Dianthus Therapeutics Inc | 1.63% |
| 5 | SYRE | Spyre Therapeutics Inc | 1.62% |
| 6 | RVMD | Revolution Medicines Inc Ordinary Shares | 1.47% |
| 7 | ORKA | Oruka Therapeutics Inc | 1.43% |
| 8 | CMPS | Compass Pathways PLC ADR | 1.43% |
| 9 | DFTX | Definium Therapeutics Inc Ordinary Shares | 1.42% |
| 10 | ALMS | Alumis Inc | 1.39% |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Inception Date: 2014-12-16